99
Domoua K, N’Dhatz M, Coulibaly G, Traore F, Koffi J, Achi V, Daix T, Outtara
Y, Ouedraogo M, Beugre LK, Konan JB, Coulibaly IM, Yapi A. Efficacy of a
short 6 month therapeutic course for HIV infected tuberculosis patients in
Abidjan, Cote d’Ivore. Bull Soc Pathol Exot 1998; 91(4):312-14
Dunlap NE, Bass J, Fujiwara P, Hopewell P, Horsburgh CR, Salfinger M, Simone
PM. Diagnostic standards and classification of tuberculosis in adults and children.
Am J Respir Crit Care Med 2000; 161: 1376-95
Fernandes GCTS, Vieira MAMS, Lourenço MC, Gadelha AJ, Coura LC, Rolla
VC. Inflamatory paradoxical reaction occuring in tuberculosis patients treated
with HAART and rifampicin. Rev Inst Med Trop S Paulo 2002; 44(2):113-4
Foudraine NA, Hovenkamp E, Notermans DW, Meenhorst PL, Klein MR, Lange
JMA, Miedema F, Reiss P. Immunopathology as a result of highly active
antiretroviral therapy in HIV-1 infected patients. AIDS 1999; 13:177-84
Friedland G, Khoo S, Jack C, Lallo U. Administration of efavirenz (600 mg/day)
with rifampicin results in highly variable levels but excellent clinical outcomes in
patients treated for tuberculosis and HIV. J Antimicrobial Chem 2006; 58:1299-
302
Girardi E, Antonucci G, Vanacore P, Palmieri F, Matteelli A, Iemoli E, Carradori
S, Salassa B, Pasticci MB, Raviglioni MC, Ippolito G. Tuberculosis in HIV-
infected persons in the context of wide availability of highly active antiretroviral
therapy. Eur Respir J 2004; 24:11-7
Girardi E, Palmieri F, Cingolani A, Ammassari A, Petrosillo N, Gillini L, Zinzi D,
De Luca A, Antinori A, Ippolito G. Changing clinical presentation and survival in
HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir
Immune Defic Syndr 2001; 26:326-31
Goletti D, Weissman D, Jckson RW, Graham NMH, Vlahov D, Klein RS,
Munsiff SS, Ortona L, Cauda R, Fauci AS. Effect of Mycobacterium tuberculosis
on HIV replication – Role of immune activation. The Journal of Immunology
1996; 157:1271-78
Grabar S, Le Moing V, Goujard C, Leport C, Kasatchkine MD, Costagliola D,
Weiss L. Clinical outcome of patients with HIV-1 infection according to
immunologic and virologic response after 6 months of highly active antiretroviral
therapy. Ann Intern Med 2000; 133:401-10
Gray A, Karim SSA, Gengiah TN. Ritonavir/Saquinavir safety concerns curtail
antiretroviral therapy options for tuberculosis-HIV co-infected patients in
resource-constrained settings. AIDS 2006; 20: 302-3